NCT06937593View on ClinicalTrials.gov

A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 13, 2025

Primary Completion Date

January 6, 2026

Study Completion Date

February 13, 2026

Conditions

Healthy

Interventions

DRUG

VIS954

A humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)

DRUG

Placebo

VIS954 Placebo

Trial Locations (1)

92801

Anaheim Clinical Trials, LLC, Anaheim

All Listed Sponsors

lead

Visterra, Inc.

INDUSTRY

NCT06937593 - A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954 | Biotech Hunter | Biotech Hunter